ARS Pharmaceuticals Q1 revenue hits $22.7M as Neffy sales scale

ARS Pharmaceuticals (NASDAQ:SPRY) reported its first-quarter 2026 financial results, highlighted by accelerating domestic sales for its needle-free allergy treatment alongside a broadening international regulatory footprint.

The San Diego-based biopharmaceutical firm posted total revenue of $22.7 million for the three months ended March 31, 2026.

The top-line performance was heavily driven by its core product, neffy® (epinephrine nasal spray), which generated $17.5 million in U.S. net product revenue during the quarter, indicating sustained market penetration for the first non-injectable treatment approved for severe Type I allergic reactions.

As the company transitions from a clinical-stage developer to a fully operational commercial enterprise, its expenses reflected aggressive market deployment.

ARS Pharmaceuticals reported a net loss of $60.6 million for the quarter, driven by elevated selling, general, and administrative outlays to support its commercial infrastructure.

The firm remains well-capitalized to fund its ongoing rollout, concluding the period with $201 million in cash, cash equivalents, and short-term investments.

Operationally, the company expanded its boots-on-the-ground presence to capture broader prescriber adoption, completing a field sales force expansion to a total of 148 specialized representatives.

To ensure retail affordability and clear insurance hurdles, management is advancing a point-of-sale retail pharmacy program to cap out-of-pocket costs at $199 for uncovered claims, while simultaneously pushing a major access proposal with CVS Caremark through its final approval stages.

Beyond the initial domestic launch, the company secured critical regulatory updates to expand its addressable patient demographic.

The U.S. Food and Drug Administration approved a label expansion that removes the baseline age restrictions from the neffy 1 mg dosage.

On the global front, the company achieved new commercial entry points following comprehensive marketing approvals from Health Canada and the European Commission.